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An increasing body of evidence indicates that nondip-
htheria corynebacteria may be responsible for respiratory 
tract infections. We report an outbreak of Corynebacterium 
pseudodiphtheriticum infection in children with cystic ﬁ  bro-
sis (CF). To identify 18 C. pseudodiphtheriticum strains iso-
lated from 13 French children with CF, we used molecular 
methods (partial rpoB gene sequencing) and matrix-assist-
ed laser desorption ionization time-of-ﬂ  ight  (MALDI-TOF) 
mass spectrometry. Clinical symptoms were exhibited by 10 
children (76.9%), including cough, rhinitis, and lung exacer-
bations. The results of MALDI-TOF identiﬁ  cation matched 
perfectly with those obtained from molecular identiﬁ  cation. 
Retrospective analysis of sputum specimens by using spe-
ciﬁ  c real-time PCR showed that ≈20% of children with CF 
were colonized with these bacteria, whereas children who 
did not have CF had negative test results. Our study reem-
phasizes the conclusion that correctly identifying bacteria at 
the species level facilitates detection of an outbreak of new 
or emerging infections in humans. 
C
ystic ﬁ  brosis (CF) is an autosomal recessive disease 
characterized by defective ion channels, resulting in 
multiorgan dysfunction, most notably affecting the respira-
tory tract. The alteration in pulmonary environment is asso-
ciated with increased susceptibility to bacterial infections 
(1,2). These bacterial infections and the ensuing inﬂ  am-
mation damage the airway epithelium and cause recurrent 
episodes of acute exacerbations, leading ultimately to re-
spiratory failure. Respiratory infections account for 80%–
90% of deaths of patients with CF (2). Recent advances in 
bacterial taxonomy and improved microbial identiﬁ  cation 
methods have led to increasing recognition of the complex-
ity of microbial ecology of the CF lung (3–5). Thus, infec-
tions of the lung in patients with CF are now considered 
as polymicrobial infections. In addition to well recognized 
CF pathogens (e.g., Staphylococcus aureus, Pseudomonas 
aeruginosa,  Haemophilus inﬂ  uenzae, and Burkholderia 
cepacia complex) numerous other opportunistic bacteria 
have been recently reported, such as Stenotrophomonas 
maltophila, Achromobacter xylosoxydans, and Inquilinus 
limosus and methicillin-resistant S. aureus and mucoid P. 
aeruginosa (1,2,6–8). 
The ﬁ  rst difﬁ  culty in studying infections in the lungs 
of patients with CF is that many bacteria present in the 
lung cannot be isolated from sputum either because of their 
fastidious growth requirements or because of the presence 
of other more common CF-related pathogens, including 
P. aeruginosa, S. aureus, H. inﬂ  uenzae, and Branhamella 
catarrhalis, that might ordinarily overgrow other bacte-
ria in culture. Second, correct identiﬁ  cation of bacteria in 
patients with CF remains challenging because phenotype 
variation is a common feature during chronic infection of 
the lung (4,9). Consequently, the list of bacteria that can be 
recovered from sputum specimens of patients with CF may 
be underestimated, and new or emerging bacteria that could 
be responsible for outbreaks in this population are not eas-
ily detected. Correct identiﬁ  cation of these bacteria is not 
easily achieved.
Several studies have reported the use of matrix-assisted 
laser desorption ionization time-of-ﬂ  ight (MALDI-TOF) 
mass spectrometry as a powerful tool with good and repro-
ducible results for rapid identiﬁ  cation of clinical isolates in 
the microbiology laboratory (10) as well as for identifying 
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nonfermenting gram-negative bacteria in patients with CF 
(11–13). This method is simple, rapid, easy to perform, in-
expensive, and may ultimately replace routine phenotypic 
assays (10).
We report the clinical and microbiologic features 
of patients with CF who were infected or colonized by 
C. pseudodiphtheriticum. The index case-patient was a 
9-year-old girl with fever and cough; a coryneform bacte-
rium was isolated in pure culture from her sputum. After 
this ﬁ  rst case, several other children with CF were found 
to be infected by coryneform bacteria; thus, we decided to 
investigate the possibility of an endemic transmission in 
this population. Isolated strains were identiﬁ  ed by using 
existing phenotypic and molecular methods (14) as well as 
MALDI-TOF to decipher the relationship between these 
strains. Finally, a new real-time PCR with TaqMan probe 
(Applied Biosystems, Courtaboeuf, France) was developed 
and used in a retrospective analysis to detect these coryne-
form bacteria in our population with CF.
Methods
Sample Collection and Bacteriologic Culture
From August 2005 through June 2008, sputum sam-
ples, bronchoalveolar lavage samples, or both, were col-
lected from patients with CF at 2 cystic ﬁ  brosis treatment 
centers (CFTCs), Timone Children’s Hospital (patients 
<18 years of age; CFTC1) and Ste. Marguerite Hospital 
in Marseille (patients >18 years of age; CFTC2). Only 
samples that showed, by direct Gram staining, infrequent 
epithelial cells (<10 cells/ﬁ  eld) and numerous polymor-
phonuclear cells (>25 cells/ﬁ  eld) were further analyzed 
and processed according to current local guidelines (4). 
A portion of each sample was also frozen at –20°C for 
further study. Respiratory samples from patients who did 
not have CF (children admitted to the pediatric health-
care center and adults admitted to CFTC2) were also col-
lected for control analysis. The Corynebacterium refer-
ence strains used in this study are listed in the Table. This 
study was approved by our local ethics committee (no. 
07–011).
Phenotypic Identiﬁ  cation
The positive bacilli from respiratory samples, identiﬁ  ed 
by Gram stain, were investigated by metabolic tests, as oxi-
dase and catalase activities, and by the use of Api (RAPID) 
Coryne Database 2.0 system (bioMérieux, Marcy-l’Etoile, 
France) (15). The antimicrobial drug susceptibility testing 
was performed by disk diffusion method on Mueller-Hinton 
agar with 5% sheep blood incubated for 24 h at 37°C.
Genotypic Identiﬁ  cation and Sequence Analysis 
Primers used in this study for ampliﬁ  cation and se-
quencing the partial rpoB gene as well as PCR methods 
have been previously described (16). Multiple sequence 
alignment and percentage of similarities for the partial rpoB 
genes between the different species of corynebacteria were 
done by using the ClustalW program on the EMBL-EBI 
web server (www.ebi.ac.uk/clustalw). A phylogenic tree 
was generated by using the neighbor-joining method from 
MEGA 4.0 software (www.megasoftware.net). Kimura 
2-parameter was used as a substitution model to construct 
the rpoB tree. Bootstrap replicates were performed to es-
timate the reliabilities of the nodes of the phylogenic tree 
obtained.
Bacterial Analysis by MALDI-TOF Mass Spectrometry
The strains were plated on Columbia agar with 5% 
sheep blood (COS) (bioMérieux) and incubated for 24 h at 
37°C. One isolated colony from each strain was harvested 
and deposited on a target plate (Bruker Daltonics, Bre-
men, Germany) in 3 replicates. Two microliters of matrix 
solution (saturated α-cyano-4-hydroxycinnamic acid, 50% 
acetonitrile, 2.5% triﬂ  uoroacetic acid) was then added and 
samples were processed in the MALDI-TOF mass spec-
trometry (337 nm) (Autoﬂ  ex, Bruker Daltonics with the 
ﬂ  ex control software) (10). The proﬁ  les were compared and 
analyzed by Biotyper 2.0 (Bruker Daltonics) and ﬁ  nally a 
dendrogram of mass spectral data was constructed by us-
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Table. Strains used to test the specificity of quantitative PCR and 
Ct obtained in a study of Corynebacterium pseudodiphtheriticum
infection in CF patients, France, August 2005–June 2008* 
Corynebacterium spp. Reference Ct
C. accolens CIP104783T 38
C. afermentans subsp. afermentans CIP103499T –
C. afermentans subsp. lipophilum CIP103500T –
C. amycolatum CIP103452T –
C. coyleae CIP104919T –
C. diphteriae CIP100721T –
C. durum CIP105490T 39
C. freneyi CIP106767T –
C. glucuronolyticum CIP104577T –
C. imitans CIP105130T –
C. jeikeium Blood culture  –
C. macginleyi CIP104099T –
C. minutissimum CIP100652T –
C. mucifaciens CIP105129T –
C. propinquum CIP103792T 23
C. pseudodiphtheriticum CIP103420T 21
C. riegelii CIP105310T 38
C. seminal CIP104297T –
C. singular CIP105491T –
C. striatum CIP81.15T –
C. ulcerans CIP106504T –
C. urealyticum CIP103524T –
C. xerosis CIP100653T –
C. aurimucosum CCUG 47449T  –
C. fastidiosum CIP103808 –
*CF, cystic fibrosis; Ct, cycle threshold; –, negative. C. pseudodiphtheriticum and CF 
ing the instructor default setting. The Biotyper 2.0 program 
generates the tree depending on distance-based method and 
does not provide branch support values.
Real-time PCR
A new real-time PCR with a TaqMan probe (Applied 
Biosystems) that targets the rpoB gene of C. pseudodiph-
theriticum has been developed and tested retrospectively 
in sputum samples that had previously been collected in 
a 1-year study from January through December 2006. 
Sputum samples from 4 groups of patients were ana-
lyzed: sputum samples from child (group 1) and adult 
(group 2) CF patients and sputum samples from non-CF 
children (group 3) and from non-CF adults (group 4). 
Primers and probe used were as follows: CorynPF (5′-
GACGGYGCTTCCAACGAAGA-3′) and CorynPR (5′-
CCGACGGAGATCGGGTGC-3′) and probe CorynPr 
(6FAM-TCTGTTGGCTAACTCCCGYCCAAA-TAM-
RA). Speciﬁ  city of these primers and probe was veriﬁ  ed 
in silico by using the BLAST program (www.ncbi.nlm.nih.
gov/BLAST) as well as by using corynebacteria reference 
strains (Table). Sensitivity was assessed by using tenfold 
serial dilutions of a 0.5 MacFarland inoculum.
Results
Patients and Samples
Overall, 229 patients with CF were monitored from 
August 2005 through June 2008 in the 2 CFTCs in Mar-
seille (118 children and 111 adults). During this period, 18 
corynebacteria were isolated from respiratory samples of 
13 children with CF (11.0%) but none from adults with CF 
(p<0.001). Details for the 13 patients are given in the online 
Appendix Table (www.cdc.gov/EID/content/16/8/1231-
appT.htm). The mean age was 4.3 (0.3–16) years, and the 
sex ratio (M:F) was 0.6. Isolation of C. pseudodiphtheriti-
cum was associated with clinical symptoms in 10 patients 
(76.9%), including cough, rhinitis, asthma crisis, and lung 
exacerbations (online Appendix Table). The culture of C. 
pseudodiphtheriticum from respiratory samples was pure in 
6 cases (in 2 cases, patients had clinical symptoms). For 4 
patients, a Corynebacterium isolate was obtained on >1 oc-
casion (online Appendix Table). Six patients were treated, 
including 3 with β-lactams only, 1 with a combination of 
a β-lactam and cotrimoxazole, 1 with cotrimoxazole alone, 
and 1 with cotrimoxazole alone initially and then amoxicil-
lin because no improvement was noticed and the isolate 
was resistant to cotrimoxazole.
Phenotypic and Molecular Identiﬁ  cation of the Isolates
All corynebacteria were isolated from Columbia agar 
with 5% sheep blood. Colonies were white and nonhemo-
lytic. They were all catalase positive and oxidase negative. 
The use of the ApiCoryne 2.0 system yielded identiﬁ  cation 
of 16 C. pseudodiphtheriticum and 1 C. propinquum, with 
a conﬁ  dence level 83%–99% (online Appendix Table). The 
remaining isolate was poorly identiﬁ  ed as Brevibacter sp. 
with an uninterpretable pattern (online Appendix Table). 
All isolates were susceptible to β-lactams, vancomycin, 
rifampin, gentamicin, and doxycycline, whereas there 
was heterogeneity of susceptibility for erythromycin and 
cotrimoxazole (online Appendix Table). The partial rpoB 
gene sequencing provided an accurate identiﬁ  cation for 18 
isolates (A1 to M) with similarity >97% compared with 
reference strains (online Appendix Table). The results of 
the MALDI-TOF identiﬁ  cation matched perfectly with the 
partial rpoB sequencing identiﬁ  cation for all the isolates; 
mean score values were 1.8–2.5 (online Appendix Table). 
Figure 1 presents 2 trees built by using MALDI-TOF mass 
spectrometry (Figure 1, panel A) and by using partial rpoB 
gene sequences (Figure 1, panel B). Although comparison 
between these 2 trees was impossible because of the dif-
ferent methods used (i.e., Euclidean distance method for 
MALDI-TOF dendrogram and neighbor-joining method 
for phylogenetic tree), the 2 trees gave a similar clustering 
of the isolates (Figure 1).
Real-time PCR
Sensitivity of our new real-time PCR ranged from 
5 CFU/mL to 10 CFU/mL; speciﬁ  city for C. pseudodiph-
theriticum was veriﬁ  ed by testing Corynebacterium spp. 
reference strain cultures with C. propinquum, the most 
closely related species, which was also ampliﬁ  ed. A low 
level of cross-ampliﬁ  cation was also observed in 3 other 
species with cycle thresholds (Ct) >38 cycles, including 
C. accolens, C. durum, and C. riegelii (Table); this ﬁ  nd-
ing could not be considered clinically relevant. To estimate 
the prevalence of this bacterium in our CF population, we 
used the real-time PCR to test, retrospectively and blindly,   
all respiratory samples available from January through De-
cember 2006 from 146 patients with CF (n = 356 sputum 
samples; 86 children, group 1; and 60 adults, group 2) and 
from 56 patients without CF (n = 67 sputum samples; 18 
children, group 3; and 38 adults, group 4). We found 24 
PCR-positive sputum specimens (Ct <37) in 17 children 
(19.8%) and 3 adults (5%) in patients with CF (Figure 2). 
Among these 24 PCR-positive samples only 2 were culture 
positive (sample A1, online Appendix Table) (p<0.0001). 
Thus, 16 additional children and 3 adult patients with CF 
were eventually colonized with this bacterium. For the con-
trol group, although all samples were culture negative, we 
found 3 PCR-positive samples in 2 adult patients, who were 
followed up in CFTC2 for lung transplantation, and none 
from children (Figure 2). The 2 PCR-positive lung-trans-
plant patients were hospitalized in the adult CFTC with 2 
adult patients with CF during the same period. For these 2 
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patients, cultures of sputum samples were polymicrobial, 
and ﬁ  ndings were interpreted as normal ﬂ  ora. Finally, the 
number of PCR-positive children with CF was signiﬁ  cantly 
higher than the number of either children without CF or 
adults with CF (p = 0.03 and p = 0.01, respectively; Figure 
2). Conversely, this difference was not signiﬁ  cant between 
adult patients with CF and adult patients without CF (Fig-
ure 2). Notably, the 18 children who did not have CF were 
seen by clinicians in the same hospital, but not in the same 
healthcare center, and were not in contact with CF children. 
Thus, the only risk factor found for being infected or colo-
nized with C. pseudodiphtheriticum was to be monitored at 
the CF center.
Discussion
We report the isolation of C. pseudodiphtheriticum in 
children with CF who had respiratory disease, mainly cough 
and rhinitis. As reemphasized in our study, this group of or-
ganisms is poorly identiﬁ  ed by current phenotypic methods 
that lack speciﬁ  city and result in ambiguous or even erro-
neous identiﬁ  cation. These bacteria are usually considered 
as part of the natural ﬂ  ora of the respiratory tract, skin, and 
mucous membranes (17) and are not reported to clinicians. 
Moreover, culture of bacteria from sputum samples of pa-
tients with CF is known to lack sensitivity, either because 
of the fastidious nature of several organisms or because of 
overgrowth by common bacteria such as mucoid P. aerugi-
nosa ( 4,5). For these reasons, an outbreak in a speciﬁ  c 
population of patients such as patients with CF may easily 
go unnoticed. 
Our study shows that correct identiﬁ  cation of bacte-
ria remains critical for detecting such a possibility and that 
surveillance of the circulation of bacteria within patients 
with CF should be addressed in the future so new or emerg-
ing pathogens can be detected. For this purpose, we even-
tually identiﬁ  ed the isolates by using PCR ampliﬁ  cation 
and sequencing of the rpoB gene (currently the standard 
method) (16) and compared the ﬁ  ndings to those obtained 
with the MALDI-TOF mass spectrometry method. Interest-
ingly, the bacteria identiﬁ  ed were exactly the same with 
both methods. This result suggests MALDI-TOF may rep-
resent a rapid inexpensive alternative assay for identiﬁ  ca-
tion of these bacteria at the species level as recently re-
ported for routine identiﬁ  cation of bacteria (10). Moreover, 
both methods were highly discriminatory and allowed us to 
demonstrate that patients were infected or colonized by C. 
pseudodiphtheriticum. The dendogram obtained with the 
MALDI-TOF technique for identiﬁ  cation of C. pseudodiph-
theriticum was in general agreement with that of a partial 
rpoB gene sequencing phylogenetic tree, but identiﬁ  cation 
of the strains at the species level could be obtained within 
minutes. Further studies to evaluate the typing power of 
MALDI-TOF mass spectrometry to discriminate bacterial 
strains below the species level should be done. In addition, 
the correct identiﬁ  cation of the bacteria was the critical step 
in designing a new tool, i.e., a speciﬁ  c real-time quantita-
tive PCR, to investigate the presence of an outbreak in the 
CF population.
The importance of positive cultures for nondiphtheria 
corynebacteria obtained from clinical samples of patients 
with signs and symptoms should not be overlooked (18). 
Although nondiphtheria corynebacteria were historically 
considered as contaminants without clinical signiﬁ  cance, 
an increasing body of evidence shows their pathogenicity, 
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Figure 1. Phylogenetic tree showing 
the position of Corynebacterium spp. 
isolated in patients with cystic ﬁ  brosis 
based on comparisons of the mass 
spectra obtained with matrix-assisted 
laser desorption ionization time-of-
ﬂ  ight (MALDI-TOF) mass spectrometry 
(A) and of sequences of the partial RNA 
polymerase β-subunit gene rpoB (B). 
For MALDI-TOF, a tree was constructed 
with Biotyper 2.0 software (Bruker 
Daltonics, Bremen, Germany) using 
Euclidean distance. The rpoB tree was 
constructed by the neighbor-joining 
method and a maximum likelihood-
based distance algorithm and numbers 
on branches indicate the bootstrap 
values derived from 500 replications. 
*Reference strains (Mycobacterium 
tuberculosis H37Rv, C. propinquum 
CIP103792T, C. pseudodiphtheriticum 
CIP103420T).C. pseudodiphtheriticum and CF 
especially as a cause of nosocomial infection in hospitalized 
and immunocompromised patients (19). Among coryne-
form bacteria, C. pseudodiphtheriticum and C. striatum 
have been well documented as pathogens of the respira-
tory tract, leading to nosocomial and community-acquired 
pneumonia (18,20,21) as well as bronchitis, tracheitis, lung 
exacerbation, chronic obstructive lung disease, and lung 
abscesses (22–29). 
In our study, we were initially surprised to isolate 
these bacteria in pure culture from sputa of patients with 
CF. About 70% of the patients had pulmonary symptoms, 
especially cough, and 6 (46.2%) case-patients required an-
timicrobial drug treatment. It is noteworthy that these clini-
cal symptoms may be due either to coryneform toxins or 
to other respiratory pathogens, including viruses that were 
not investigated in this study. Surprisingly, 4 of 13 chil-
dren had >1 isolate during the study period, which suggests 
that patients with CF become chronically colonized with C. 
pseudodiphtheriticum. Because of the difﬁ  culty in isolating 
these bacteria in respiratory samples, except for those that 
are in pure culture, their prevalence within the CF popula-
tion may well be underestimated. This hypothesis was sup-
ported by the retrospective detection of DNA in additional 
sputum specimens from children with CF whose culture 
results were negative (≈20% of positive children) and adult 
patients by using our speciﬁ  c real-time PCR. We found that 
C. pseudodiphtheriticum was signiﬁ  cantly associated with 
children with CF, which suggests transmission between 
patients with CF may have occurred in the CF healthcare 
center because none of the children without CF who were 
seen in a separate healthcare center (a different ﬂ  oor in the 
hospital) were PCR positive. 
Patient-to-patient transmission could not be excluded 
and should be further investigated because 2 adult patients 
without CF who had PCR-positive specimens were detect-
ed in the same adult CFTC where they likely had contact 
with 2 PCR-positive CF adult patients. Such transmission 
has been recently demonstrated for C. striatum as a cause 
of nosocomial outbreak and respiratory colonization 
in patients with chronic obstructive pulmonary disease 
(30). Similarly, an outbreak of clonal multidrug-resistant 
strains of C. striatum as an emerging agent of pulmonary 
disease has been recently reported in Italy (21). Further 
epidemiologic studies are warranted to deﬁ  ne the role of 
C. pseudodiphtheriticum transmission in the course of 
CF disease in other CF centers. Finally we believe that 
the implementation of isolation or segregation measures 
should be the rule in CF centers to reduce the risk of trans-
mission of pathogens.
In conclusion, corynebacteria may colonize the respi-
ratory tract of CF patients. Although the clinical importance 
of C. pseudodiphtheriticum in the complex setting of CF 
patients is less clear, we believe that this bacterium should 
be added in the list of new or emerging pathogens in these 
patients. Further clinical studies are needed to establish 
whether corynebacteria may contribute to the pathology of 
lung disease in CF patients.
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